{"name":"NeuroBiogen Co., Ltd","slug":"neurobiogen-co-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTFBYWjBIVFBoM2paQTFXNC1KZnVKclFMVy1lcFRpMWR5M1NZSGZRTzA1a2o3RDNMU1VMWnN6eXdjZ3owYlNzOWliY2JsR1Bsc0VsMl9QTGNMaDRQZXZnbmF2RXFmUDNjbEJZSGEwWFdn0gFyQVVfeXFMTnM0ZFBCRC1BcXQ5RlcyVmRBZzBTb0xYV29WbkZUUklkRWo1bll6ZTBJaGhGcjdJMldRODZ4eGFUaG9xY012OUlINGRJdDZJS0RqQzFxLW5GSHlSYlRrMGxsLVNjbUdqUjl4RE5pWUVmMnZ3?oc=5","date":"2025-06-26","type":"pipeline","source":"koreabiomed.com","summary":"GCCL, NeuroBiogen advance Alzheimer’s R&D with new MAO-B biomarker assay - koreabiomed.com","headline":"GCCL, NeuroBiogen advance Alzheimer’s R&D with new MAO-B biomarker assay","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE9KbTNJZ2d2aGdPRW1Xa2tYRzdWNHZnRDJYR0x6bEV1bmR4TExPWFRFN3hLWElWZnZxdXA1b2tQTlZGVEZOM05RQ1l0WVhNTkZrenZVNG43SmhLZUVXNGF4a2hhcEladHFoNHRNUmlB0gFyQVVfeXFMUElmZmxSVzNZRkVaUEpDQ2VRZ2RERG9UUE03UzVCaG5FLVFucDlwLWR1dEkwMTBJR2pvZC11YU83dlFMSVc0cEtYdlVLRHp4eDRYVUtxeE55TW42RzlsMS1XSWJlQU9paDlDN296dWNKeTZB?oc=5","date":"2025-04-16","type":"pipeline","source":"koreabiomed.com","summary":"[Reporter’s Notebook] Is NeuroBiogen’s tisolagiline really worth $4.5 billion? - koreabiomed.com","headline":"[Reporter’s Notebook] Is NeuroBiogen’s tisolagiline really worth $4.5 billion?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0wFBVV95cUxNUFc5czhtUHhqUTh3bC0wSFFyMGNNcmR4dnVFOUlmVmlZdDV5VHppdUtaMk5GM0c0d0w5LW8ydXdyVllkV0VlU0hhWDd4THpUblpsemxsSjl0UmVPeldqdkNRN3lncFIyQ3FoOFF3anFOZWlnWXVUZkZUb3hSM29Mc1JFcklFbHR2V2ZLZTBuQVY3ZjEzVDBscW5uekN0T1IyOVFIM1AtVjBxYUZpRUlvLVhtRmJxNDFvN2Q1RkFFcjRjNlZKckdJWm1aUXF1Z2g0bDIw?oc=5","date":"2024-12-11","type":"trial","source":"Quiver Quantitative","summary":"Scilex Bio Announces Ongoing Phase 2 Trial for KDS2010 in Obesity Treatment, Expanding to U.S. in 2025 - Quiver Quantitative","headline":"Scilex Bio Announces Ongoing Phase 2 Trial for KDS2010 in Obesity Treatment, Expanding to U.S. in 2025","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2024-12-10","type":"pipeline","source":"GlobeNewswire","summary":"NeuroBiogen Company and Scilex Bio, a Controlling Interest - GlobeNewswire","headline":"NeuroBiogen Company and Scilex Bio, a Controlling Interest","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}